Revvity Opera Phenix Plus: high-content screening system in focus for US labs

Revvity's Opera Phenix Plus high-content screening system targets drug discovery and cell biology labs with fast, confocal imaging and multiplexed assay capabilities. We look at what the instrument offers, where it fits in, and how it is positioned for US researchers.

Responsible: ad hoc news Lifestyle & Consumer Desk. Reviewed prior to publication on June 12, 2026 at 12:11:10 PM ET. Details in the imprint.

Revvity's Opera Phenix Plus high-content screening system is one of the company’s flagship imaging platforms for phenotypic drug discovery and advanced cell biology. Designed as a confocal, automated microscope optimized for high-throughput screening, the system combines fast image acquisition with sensitive detection for multiplexed assays in microplate formats. In the US market, Opera Phenix Plus targets pharma and biotech discovery labs, academic screening centers, and core facilities that need to push throughput and image quality beyond what conventional widefield instruments can deliver.

High-content imaging platform aimed at demanding discovery workflows

The Opera Phenix Plus platform is built around spinning-disk confocal optics that allow simultaneous imaging of multiple fluorescence channels with reduced crosstalk, which is critical for complex phenotypic assays that rely on several markers in the same cell. According to Revvity materials, the system is designed for high-content screening in 96, 384, and 1,536-well plate formats, supporting both fixed and live-cell applications commonly used in early drug discovery and mechanism-of-action studies. Spinning-disk confocal designs typically enable higher acquisition speeds than point-scanning confocal microscopes, which matters when labs need to image millions of cells across thousands of wells.

Revvity positions Opera Phenix Plus as a premium system in its high-content portfolio, with features such as water-immersion objectives to improve numerical aperture and light collection efficiency for live-cell imaging. Water-immersion optics help capture finer details in 3D structures and improve signal-to-noise ratios in thick samples compared with standard air objectives at the same magnification. For discovery labs using organoids, 3D spheroids, or complex co-culture models, this capability can be an important differentiator versus simpler imaging plate readers or basic automated microscopes that may struggle with depth and resolution.

Automation is central to the system’s value proposition. Opera Phenix Plus integrates motorized stages, autofocus routines, and plate-handling hardware to run unattended screening campaigns, with software to define imaging workflows and analysis pipelines. By allowing users to script multiple imaging sequences and analysis steps, the platform aims to reduce manual intervention and operator time, which can be a constraint in traditional microscopy workflows that rely on manual focus, field selection, and post-processing. For labs managing screening campaigns across diverse cell lines and assay formats, this automation can support more consistent data generation and higher throughput.

Revvity ties the Opera Phenix Plus instrument into its broader software ecosystem, including high-content analysis solutions that can classify phenotypes, quantify morphological changes, and extract multiparametric descriptors from large image datasets. High-content imaging can generate terabytes of data in multi-week campaigns, and integrated analysis tools are essential to turn raw images into actionable endpoints such as cell health, target engagement, or signaling pathway modulation. The system is therefore positioned not merely as a microscope, but as part of an end-to-end high-content screening workflow spanning reagents, plates, imaging hardware, and analytics.

US buyers considering the Opera Phenix Plus typically compare it with other high-content platforms and advanced imaging readers in a similar price band, where the combination of confocal optics, water-immersion objectives, and fast automation are key differentiating points. While Revvity does not publish list pricing on its site, high-content screening instruments of this class generally sit in a six-figure US dollar range depending on configuration, objectives, lasers, and software licenses, and are commonly acquired by institutional buyers through capital budgets or leasing programs. Service and maintenance contracts are a significant component of total cost of ownership, particularly for high-duty-cycle use in industrial screening labs.

In the company’s broader portfolio, Opera Phenix Plus sits alongside other detection platforms, reagents, and software used in life science research and diagnostics. Revvity has emphasized technology-enabled solutions for life sciences and applied markets, and high-content imaging instruments form part of that strategy by enabling customers to run more complex cellular assays on a single automated platform. Shares of Revvity Inc. (US76155R1086, ticker RVTY) traded at about $100.22 on NYSE on June 12, 2026.

Opera Phenix Plus at a glance

• Product: Opera Phenix Plus high-content screening system
• Manufacturer: Revvity Inc.
• Category: Lifestyle / Consumer (high-content imaging platform for research labs)
• Launch date: Not publicly specified; current generation model available in the mid-2020s
• MSRP / Price: Not publicly listed; typically a six-figure US dollar capital instrument depending on configuration
• Availability: Direct sales and authorized distributors in the US; ordering and contact options via Revvity sales channels
• Target audience: Pharma and biotech discovery groups, academic screening centers, contract research organizations, and advanced cell biology labs
• Key feature / USP: High-throughput, spinning-disk confocal imaging with water-immersion objectives and integrated automation for complex phenotypic screening

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.